Novartis new two-year data with Certican® shows positive outcomes at 24 months in largest liver transplant trial to date
12 November 2012 | By Novartis
New two-year results...
List view / Grid view
12 November 2012 | By Novartis
New two-year results...
11 November 2012 | By Novartis
New data from two Phase II trials of ACZ885...
8 November 2012 | By Novartis
Update on leading R&D pipeline...
7 November 2012 | By Novartis
Committee votes unanimously in favor of Signifor (pasireotide)...
7 November 2012 | By Novartis
RELAX-AHF study met one of its two primary endpoints...
5 November 2012 | By Novartis
European Commission approval for Votubia®...
1 November 2012 | By Edelman
NEJM published results...
31 October 2012 | By Novartis
Novartis announced the construction of a new state-of-the-art biotechnology production site...
31 October 2012 | By Novartis
Novartis welcomes the decisions by Health Canada and Swiss Agency for Therapeutic Products, Swissmedic...
25 October 2012 | By Novartis
Confidence in the safety and efficacy of seasonal influenza vaccines...
12 October 2012 | By Novartis
Gilenya® the first once-daily oral therapy...
10 October 2012 | By Novartis
New data to be presented...
1 October 2012 | By Novartis
Seebri® Breezhaler® approved...
5 September 2012 | By Novartis
New data for Lucentis®...
3 September 2012 | By Novartis
Further data from the COPD clinical trial programs...